PBM
NUVB icon

Propel Bio Management’s Nuvation Bio NUVB Stock Holding History

Propel Bio Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-329,296
Closed -$1.41M – 33
2026
Q1 		$1.41M Buy
+329,296
New +$1.83M 0.89% 31

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Propel Bio Management's NUVB Position: Q2 2026 in Review

Propel Bio Management sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 329,296 shares — an estimated $1.41M sold.

Propel Bio Management first reported a position in NUVB in Q1 2026 and held it in 1 quarter. The position peaked at $1.41M in Q1 2026. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Propel Bio Management reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 329,296 Nuvation Bio shares in Q2 2026, an estimated $1.41M.
  • Propel Bio Management first reported a position in Nuvation Bio in Q1 2026 and held it in 1 quarter.
  • Propel Bio Management's Nuvation Bio position peaked at $1.41M in Q1 2026.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.